Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-12-07

Clinical Trial Update: LANTUSTITR: Insulin Glargine in Type 2 Diabetes Mellitus [Phase 4]

View source ↗

Summary

A Phase 4 trial of insulin glargine (Lantus) for type 2 diabetes mellitus has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Lantus (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: TERMINATED